Previous Article | Next Article 
Infection and Immunity, November 2003, p. 6686, Vol. 71, No. 11
0019-9567/03/$08.00+0 DOI: 10.1128/IAI.71.11.6686.2003
Humoral Immunity against Bordetella pertussis: Antibodies or B Cells?

LETTER
Kirimanjeswara et al. (
5) studied the role of B cells and antibodies
in immunity to
Bordetella by using murine infection models for
Bordetella bronchiseptica and the human pathogens
B. pertussis and
B. parapertussis. They showed that although B cells are
required for efficient clearance of all three
Bordetella species,
intraperitoneal injection of murine immune sera results in clearance
of
B. bronchiseptica, whereas the human pathogens persist. From
these data and results of previously published studies which
failed to show opsonic activity of human immune sera in vitro
(
7), they conclude that
Bordetella species that are pathogenic
for humans may have acquired the capacity to evade the human
humoral immune response (
5). The study by Kirimanjeswara and
colleagues is a valuable contribution to the field. However,
an alternative explanation for their results should not remain
unmentioned.
Recently published studies have clearly shown that human immune sera efficiently induce leukocyte effector functions towards B. pertussis (6). Bordetella-specific immunoglobulin G (IgG) and IgA were shown to be capable of inducing phagocytosis, respiratory burst, and bacterial killing (2, 6). It was furthermore shown that B. pertussis is less efficiently cleared from mice deficient for IgG receptors (Fc
R) (3, 4), which suggests that IgG is also crucial for the induction of leukocyte effector functions in vivo. Taken together, these data challenge the conclusion by Kirimanjeswara et al. that Bordetella species that are pathogenic for humans have acquired the capacity to evade humoral immune responses.
We feel that data from studies using the combination of inbred mouse strains and human pathogens should be interpreted with care. Their limited major histocompatibility complex repertoire may preclude the generation of a specific immune response of sufficient diversity, which is required for efficient host defense. Although Kirimanjeswara et al. showed that antibody titers and IgG subclass profiles did not differ between mice infected with murine Bordetella pathogens and those infected with human Bordetella pathogens (5), they did not document antibody specificities. Importantly, recent studies showed that not all Bordetella-specific antibodies trigger phagocyte effector functions; rather, opsonic activity of sera primarily depends on the presence of specific antibody subsets. Only pertactin-specific antibodies in human immune sera displayed opsonic activity and induced phagocytosis by human leukocytes (1). Although it remains to be established which B. bronchiseptica-specific antibodies (pertactin specific or others) display opsonic activity, documenting the specificity in addition to antibody titers in sera from mice seems mandatory for the interpretation of the results obtained by Kirimanjeswara et al. We look forward to sharing this information with them in the near future.

REFERENCES
1 - Hellwig, S. M., M. E. Rodriguez, G. A. M. Berbers, J. G. J. van de Winkel, and F. R. Mooi. 2003. Crucial role of pertactin antibodies in Bordetella pertussis immunity. J. Infect. Dis. 188:738-742.[CrossRef][Medline]
2 - Hellwig, S. M., A. B. van Spriel, J. Schellekens, F. R. Mooi, and J. G. J. van de Winkel. 2001. IgA-mediated protection against Bordetella pertussis infection. Infect. Immun. 69:4846-4850.[Abstract/Free Full Text]
3 - Hellwig, S. M., H. F. van Oirschot, W. L. W. Hazenbos, A. B. van Spriel, F. R. Mooi, and J. G. J. van de Winkel. 2001. Targeting to Fc
receptors, but not CR3 (CD11b/CD18), increases clearance of Bordetella pertussis. J. Infect. Dis. 183:871-879.[CrossRef][Medline]
4 - Ioan-Facsinay, A., S. J. de Kimpe, S. M. Hellwig, P. L. van Lent, F. M. Hofhuis, H. H. van Ojik, C. Sedlik, S. A. da Silveira, J. Gerber, Y. F. de Jong, R. Roozendaal, L. A. Aarden, W. B. van den Berg, T. Saito, D. Mosser, S. Amigorena, S. Izui, G. J. van Ommen, M. van Vugt, J. G. van de Winkel, and J. S. Verbeek. 2002. Fc
RI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses and protection from bacterial infection. Immunity 16:391-402.[CrossRef][Medline]
5 - Kirimanjeswara, G. S., P. B. Mann, and E. T. Harvill. 2003. Role of antibodies in immunity to Bordetella infections. Infect. Immun. 71:1719-1724.[Abstract/Free Full Text]
6 - Rodriguez, M. E., S. M. M. Hellwig, D. F. Hozbor, J. Leusen, W.-L. van der Pol, and J. G. J. van de Winkel. 2001. Fc receptor-mediated immunity against Bordetella pertussis. J. Immunol. 167:6545-6551.[Abstract/Free Full Text]
7 - Weingart, C. L., and A. A. Weiss. 2000. Bordetella pertussis virulence factors affect phagocytosis by human neutrophils. Infect Immun. 68:1735-1739.[Abstract/Free Full Text]
| | | | | |
María Eugenia Rodriguez1*
CINDEFI School of Science, National University of La Plata, La Plata, Argentina,1
W.-Ludo van der Pol2
Departments of Immunology and Neurology, University Medical Center, Heidelberglaan 100, 3584CX Utrecht, The Netherlands,2
|
| | | | | |
* Phone: 54 221 4833794, Fax: 54 221 4833794, E-mail: mer{at}quimica.unlp.edu.ar. |
Authors Reply

LETTER
We are in agreement with Drs. Rodriguez and van der Pol that
antibodies are important in the clearance of
B. pertussis, as
demonstrated in our paper and previously by multiple groups.
Our discussion focused on the observation that adoptively transferred
antibodies clear
B. bronchiseptica, but not
B. pertussis, within
3 days, and we offer differential antigen recognition as one
possible explanation. It is well-established that adoptively
transferred antibodies require more than 1 week to clear
B. pertussis from naive mice, and the contribution of different
antigens is a topic of investigation in multiple laboratories.
| | | | | |
Girish S. Kirimanjeswara Paul B. Mann Eric T. Harvill*
Department of Veterinary Science, The Pennsylvania State University, 115 Henning Building, University Park, PA 16802,3
|
| | | | | |
* Phone: (814) 863-8522, Fax: (814) 863-6140, E-mail: eth10{at}psu.edu. |
Infection and Immunity, November 2003, p. 6686, Vol. 71, No. 11
0019-9567/03/$08.00+0 DOI: 10.1128/IAI.71.11.6686.2003
This article has been cited by other articles:
-
Gianfrani, C., Levings, M. K., Sartirana, C., Mazzarella, G., Barba, G., Zanzi, D., Camarca, A., Iaquinto, G., Giardullo, N., Auricchio, S., Troncone, R., Roncarolo, M.-G.
(2006). Gliadin-Specific Type 1 Regulatory T Cells from the Intestinal Mucosa of Treated Celiac Patients Inhibit Pathogenic T Cells. J. Immunol.
177: 4178-4186
[Abstract]
[Full Text]